SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-014907
Filing Date
2021-11-08
Accepted
2021-11-08 06:15:47
Documents
63
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tbph-20210930x10q.htm   iXBRL 10-Q 2126100
2 EX-31.1 tbph-20210930xex31d1.htm EX-31.1 13466
3 EX-31.2 tbph-20210930xex31d2.htm EX-31.2 14255
4 EX-32 tbph-20210930xex32.htm EX-32 15675
  Complete submission text file 0001558370-21-014907.txt   6837191

Data Files

Seq Description Document Type Size
5 EX-101.SCH tbph-20210930.xsd EX-101.SCH 42183
6 EX-101.CAL tbph-20210930_cal.xml EX-101.CAL 52040
7 EX-101.DEF tbph-20210930_def.xml EX-101.DEF 170774
8 EX-101.LAB tbph-20210930_lab.xml EX-101.LAB 367623
9 EX-101.PRE tbph-20210930_pre.xml EX-101.PRE 287414
10 EXTRACTED XBRL INSTANCE DOCUMENT tbph-20210930x10q_htm.xml XML 1044637
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36033 | Film No.: 211386403
SIC: 2834 Pharmaceutical Preparations